TENDYNE
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 21 Oct 2025)
What this means for you
Registered since 18 Jun 2019. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 18 Jun 2029: the §8 & §9 renewal).
Record
- Serial number
- 86609447
- Registration number
- 5781874
- Mark type
- Word mark
- Filed
- 24 Apr 2015
- Published for opposition
- 29 Mar 2016
- Registered
- 18 Jun 2019
- Next maintenance filing
- §8 & §9 renewal, due by 18 Jun 2029 (grace period to 18 Dec 2029)
- Attorney of record
- Jordan M. Heinz
Goods and services
- Class 005 — Pharmaceuticals: biological replacement tissue valves for the human heart
- Class 010 — Medical apparatus: Surgical apparatus and instruments; medical devices for use in treating cardiovascular disease; replacement tissue valves comprising artificial and natural, non-living materials for the human heart; catheters; surgical instruments in the nature of repositioning tools for use in cardio-pulmonary surgical procedures
Owner
- Tendyne Holdings, Inc., Abbott Park, IL, US
- Tendyne Holdings, Inc., Abbott Park, IL, US
- Tendyne Holdings, Inc., Roseville, MN, US
Prosecution history
- 21 Oct 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 21 Oct 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 20 Oct 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 18 Jun 2025 — TEAS SECTION 8 & 15 RECEIVED
- 18 Jun 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 18 Jun 2019 — REGISTERED-PRINCIPAL REGISTER
- 16 May 2019 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 15 May 2019 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 15 May 2019 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 15 May 2019 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 08 May 2019 — ASSIGNED TO LIE
- 02 May 2019 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 23 Apr 2019 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 23 Apr 2019 — NON-FINAL ACTION E-MAILED
- 23 Apr 2019 — SU - NON-FINAL ACTION - WRITTEN